Halozyme Therapeutics (HALO) Lowered to Hold at BidaskClub

BidaskClub lowered shares of Halozyme Therapeutics (NASDAQ:HALO) from a buy rating to a hold rating in a research note released on Tuesday morning.

Several other equities research analysts have also commented on HALO. Jefferies Group reaffirmed an underperform rating and set a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. Piper Jaffray Companies set a $20.00 price target on shares of Halozyme Therapeutics and gave the company a buy rating in a research report on Thursday, August 10th. Zacks Investment Research raised shares of Halozyme Therapeutics from a hold rating to a buy rating and set a $14.00 price target for the company in a research report on Friday, August 11th. Deutsche Bank upped their price target on shares of Halozyme Therapeutics to $20.00 and gave the company a buy rating in a research report on Friday, September 15th. Finally, BMO Capital Markets upped their price target on shares of Halozyme Therapeutics from $14.00 to $15.00 and gave the company a market perform rating in a research report on Friday, September 15th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $18.13.

Shares of Halozyme Therapeutics (HALO) opened at $18.16 on Tuesday. Halozyme Therapeutics has a 52-week low of $9.68 and a 52-week high of $19.37. The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by ($0.04). Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The business had revenue of $63.73 million for the quarter, compared to analysts’ expectations of $58.95 million. During the same period in the previous year, the company earned ($0.23) EPS. Halozyme Therapeutics’s revenue for the quarter was up 100.1% compared to the same quarter last year. sell-side analysts expect that Halozyme Therapeutics will post 0.15 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in HALO. Aperio Group LLC increased its holdings in Halozyme Therapeutics by 99.2% in the 2nd quarter. Aperio Group LLC now owns 28,823 shares of the biopharmaceutical company’s stock worth $370,000 after acquiring an additional 14,353 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Halozyme Therapeutics by 241.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 128,136 shares of the biopharmaceutical company’s stock worth $1,643,000 after acquiring an additional 90,608 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in Halozyme Therapeutics by 3.6% in the 2nd quarter. Janney Montgomery Scott LLC now owns 87,889 shares of the biopharmaceutical company’s stock worth $1,127,000 after acquiring an additional 3,015 shares in the last quarter. Sei Investments Co. increased its holdings in Halozyme Therapeutics by 8.2% in the 2nd quarter. Sei Investments Co. now owns 335,025 shares of the biopharmaceutical company’s stock worth $4,295,000 after acquiring an additional 25,300 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. increased its holdings in Halozyme Therapeutics by 11.5% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 242,000 shares of the biopharmaceutical company’s stock worth $3,103,000 after acquiring an additional 25,000 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/06/halozyme-therapeutics-halo-lowered-to-hold-at-bidaskclub.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply